GlassScriptPhysician profile
Dinakar Golla
NPI 1164561379
$28,149.51
in general payments reported to CMS, 2019-2025
48 companies · $229 in 2025
The $229 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
See the full distribution for Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $1,158 · 2021: $2,230 · 2022: $682 · 2023: $2,067 · 2024: $762 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,773 · Travel and Lodging: $1,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,772.58 |
| Travel and Lodging | $1,286.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $17,229.68 | 2019-2021 | |
| Sientra, INC. | $2,112.80 | 2019-2022 | |
| Merz North America, INC. | $1,711.48 | 2019-2021 | |
| Musculoskeletal Transplant Foundation INC. | $1,564.45 | 2022-2023 | |
| W. L. Gore & Associates, INC. | $1,089.91 | 2019-2024 | Gore Enform Preperitoneal Biomaterial |
| Galderma Laboratories, L.P. | $628.29 | 2019-2025 | Dysport, Aklief, Epsolay |
| Stability Biologics, LLC | $464.72 | 2021-2023 | |
| Tela Bio, INC. | $335.70 | 2019 | |
| Kerecis Limited | $287.50 | 2019 | |
| Smith+Nephew, INC. | $270.75 | 2019-2020 | |
| Boston Scientific Corporation | $176.42 | 2021-2023 | Avvigo Guidance System |
| Abbvie INC. | $167.88 | 2020-2022 | |
| Biofrontera INC. | $156.88 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Urgo Medical North America, LLC | $147.17 | 2023-2024 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Leo Pharma INC. | $127.13 | 2023-2025 | Adbry |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dinakar Golla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.